W
William V. Murray
Researcher at Johnson & Johnson Pharmaceutical Research and Development
Publications - 165
Citations - 2764
William V. Murray is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Aryl & Cycloaddition. The author has an hindex of 28, co-authored 164 publications receiving 2651 citations. Previous affiliations of William V. Murray include Johnson & Johnson & Janssen Pharmaceutica.
Papers
More filters
Journal ArticleDOI
1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogues as Novel and Potent Anticancer Cyclin-Dependent Kinase Inhibitors: Synthesis and Evaluation of Biological Activities
Ronghui Lin,Peter J. Connolly,Shenlin Huang,Steven K. Wetter,Yanhua Lu,William V. Murray,Stuart Emanuel,Robert H. Gruninger,Angel R. Fuentes-Pesquera,Catherine A. Rugg,Steven A. Middleton,Linda Jolliffe +11 more
TL;DR: A series of 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues synthesized as cyclin-dependent kinase (CDK) inhibitors showed potent and selective CDK1 and CDK2 inhibitory activities and inhibited in vitro cellular proliferation in various human tumor cells.
Journal ArticleDOI
Pd-catalyzed direct arylation of tautomerizable heterocycles with aryl boronic acids via C-OH bond activation using phosphonium salts.
TL;DR: Application of the Pd-catalyzed direct arylation via C-OH bond activation using PyBroP leads to the most efficient synthesis of the biologically important 6-arylpurine ribonucleoside in a single step from unactivated and unprotected inosine.
Journal ArticleDOI
Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Ronghui Lin,Sigmond G. Johnson,Peter J. Connolly,Steven K. Wetter,Eva Binnun,Terry V. Hughes,William V. Murray,Niranjan Pandey,Sandra Moreno-Mazza,Mary Adams,Angel R. Fuentes-Pesquera,Steven A. Middleton +11 more
TL;DR: 2,7-Diamino-thiazolo[4,5-d]pyrimidine analogues synthesized as novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors showed potent and selective EGFR inhibitory activities and inhibited in vitro cellular proliferation in EGFR-overexpressing human tumor cells.
Patent
Substituted amino acids as erythropoietin mimetics
Peter J. Connolly,Bandurco Victor T,Steven K. Wetter,Sigmond G. Johnson,Jacqueline C. Bussolari,William V. Murray +5 more
TL;DR: In this paper, a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture are described, which are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
Journal ArticleDOI
Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors
Gee-Hong Kuo,Alan Deangelis,Stuart Emanuel,Aihua Wang,Yan Zhang,Peter J. Connolly,Xin Chen,Robert H. Gruninger,Catherine A. Rugg,Angel R. Fuentes-Pesquera,Steven A. Middleton,Linda Jolliffe,William V. Murray +12 more
TL;DR: Molecular docking studies were conducted in an attempt to enhance the understanding of the observed structure-activity relationship and led to the discovery of [1,3,5]triazine-pyridine as a new series of potent CDK inhibitors.